- Home
- SACH vs PRLD Comparison
SACH vs PRLD Comparison
Compare SACH & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SACH
- PRLD
- Stock Information
- Founded
- SACH 2010
- PRLD 2016
- Country
- SACH United States
- PRLD United States
- Employees
- SACH N/A
- PRLD N/A
- Industry
- SACH Real Estate Investment Trusts
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- SACH Real Estate
- PRLD Health Care
- Exchange
- SACH Nasdaq
- PRLD Nasdaq
- Market Cap
- SACH 47.8M
- PRLD 50.1M
- IPO Year
- SACH 2017
- PRLD 2020
- Fundamental
- Price
- SACH $0.98
- PRLD $0.78
- Analyst Decision
- SACH Hold
- PRLD Strong Buy
- Analyst Count
- SACH 3
- PRLD 2
- Target Price
- SACH $2.25
- PRLD $4.50
- AVG Volume (30 Days)
- SACH 201.6K
- PRLD 107.5K
- Earning Date
- SACH 05-01-2025
- PRLD 05-06-2025
- Dividend Yield
- SACH 18.46%
- PRLD N/A
- EPS Growth
- SACH N/A
- PRLD N/A
- EPS
- SACH N/A
- PRLD N/A
- Revenue
- SACH N/A
- PRLD $7,000,000.00
- Revenue This Year
- SACH N/A
- PRLD N/A
- Revenue Next Year
- SACH N/A
- PRLD N/A
- P/E Ratio
- SACH N/A
- PRLD N/A
- Revenue Growth
- SACH N/A
- PRLD N/A
- 52 Week Low
- SACH $0.96
- PRLD $0.61
- 52 Week High
- SACH $3.24
- PRLD $6.80
- Technical
- Relative Strength Index (RSI)
- SACH 40.88
- PRLD 46.96
- Support Level
- SACH $0.96
- PRLD $0.73
- Resistance Level
- SACH $1.05
- PRLD $1.00
- Average True Range (ATR)
- SACH 0.04
- PRLD 0.09
- MACD
- SACH -0.00
- PRLD -0.01
- Stochastic Oscillator
- SACH 14.50
- PRLD 18.96
About SACH Sachem Capital Corp.
Sachem Capital Corp is a real estate investment trust. The company specializes in originating, underwriting, funding, servicing, and managing a portfolio of short-term loans secured by first mortgage liens on real property located in Connecticut. Its primary objective is to grow the loan portfolio while protecting and preserving capital in a manner that provides for attractive risk-adjusted returns to shareholders over the long term through dividends. The company earns majority of its revenue through Interest income from loans.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.